Skip to main content

Lupus

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

Jan 13, 2022

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.



Rheumatic and autoimmune patients were not

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

Jan 11, 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.



This was a phase II, dose-finding trial, aimed to assess

Read Article
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
Good (long) open read review of Imaging in NPSLE (CNS lupus); mainly showing there is no SPECIFIC CNS imaging finding for NPSLE. Rather imaging (CT, MRI) done to r/o other pathology. PRES, PML, Vasculopathy, White matter lesions https://t.co/baUp6kjsKr

Dr. John Cush @RheumNow( View Tweet )

Jan 11, 2022
In Mouse Model of Lupus, when the gut microbiome of NZM2410 mice colonized w/ SFB, glomerulonephritis worsened & was assoc. w/ incr in TH17, MCP-1 and CXCL1, & more microbial abundance & biodiversity (dysbiosis) https://t.co/bLxrJZKTDZ

Dr. John Cush @RheumNow( View Tweet )

Jan 10, 2022
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit!https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c
Dr. John Cush @RheumNow( View Tweet )
Jan 07, 2022
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
Safety of COVID-19 Vaccines in Rheumatic Patients A multinational study shows that the use of COVID vaccination in rheumatic and musculoskeletal disease (I-RMD) is safe, well-tolerated with very rare serious adverse events (AEs).https://t.co/d30zbfa0f8 https://t.co/OM6GzAzTvQ
Dr. John Cush @RheumNow( View Tweet )
Jan 04, 2022
Best of 2021:Danish Cohort study of 5310 cutaneous LE/SLE pts between 1995-2014 (7-8 yrs F/U & 40.724 PYs) shows overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic & lung cancers https://t.co/Lgbe2hwtNj https://t.co/NzjM5LCuaX
Dr. John Cush @RheumNow( View Tweet )
Jan 03, 2022
Best of 2021: Single center, 40 yr experience shows lupus psychosis to be rare. Among 709 SLE pts, 18 (2.5%) developed lupus psychosis. 2/3 remitted w/ antipsychotics & immunosuppressive Psychosis more likely w/ RNP and less likely w/ cardiolipin Abs. https://t.co/sKaZBqClyA https://t.co/i32kbIuEaX
Dr. John Cush @RheumNow( View Tweet )
Jan 02, 2022
Best of 2021: Single center, 40 yr experience shows lupus psychosis to be rare. Among 709 SLE pts, 18 (2.5%) developed lupus psychosis. 2/3 remitted w/ antipsychotics & immunosuppressive Psychosis more likely w/ RNP and less likely w/ cardiolipin Abs. https://t.co/JXVU9uoO4j https://t.co/SBxsgNRMr8
Dr. John Cush @RheumNow( View Tweet )
Dec 31, 2021
Best of 2021: Alveolar Hemorrhage and Mortality in Lupus Metanalysis of patients with DA), show this to be a rare and life-threatening complication of SLE, that is more apt to affect older, severe lupus patients with active infection. https://t.co/QvXiWKLTlm https://t.co/IFAS1loBId
Dr. John Cush @RheumNow( View Tweet )
Dec 30, 2021
Danish Cohort study of 5310 cutaneous LE or SLE pts between 1995-2014 (7-8 yrs F/U and 40.724 PYs) shows an overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic and lung cancers https://t.co/MFPLG9ifGU

Dr. John Cush @RheumNow( View Tweet )

Dec 29, 2021
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
FDA.approved.jpg

Best of 2021: FDA Approves Anifrolumab in SLE

Dec 24, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article
Watch: Dual BAFF/APRIL Antagonist for SLE https://t.co/ktAhM2C0i7

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations

Read Article
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Dec 21, 2021

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article
AstraZeneca announced that Saphnelo (anifrolumab - Type 1 IFN receptor MAb) was recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus https://t.co/KIBWi1Nd0F

Dr. John Cush @RheumNow( View Tweet )

Dec 20, 2021
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
×